Decoy Therapeutics's three largest insider shareholders as of September 29, 2026 are Frederick Ii Pierce (Chief Executive Officer, 34.84K shares), Mark J Rosenblum (Chief Financial Officer, 11.36K shares), Barbara Louise Hibner (Chief Scientific Officer, 4.22K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frederick Ii Pierce | Chief Executive Officer | 34,844 | 0 | 34,844 | 50.7% | 02 Sep, 2026 |
| 2 | Mark J Rosenblum | Chief Financial Officer | 11,363 | 0 | 11,363 | 16.5% | 02 Sep, 2026 |
| 3 | Barbara Louise Hibner | Chief Scientific Officer | 4,216 | 0 | 4,216 | 6.1% | 02 Sep, 2026 |
| 4 | Peter Klaus Marschel | Chief Business Officer | 3,900 | 0 | 3,900 | 5.7% | 02 Sep, 2026 |
| 5 | Arnold C Hanish | Director | 3,418 | 0 | 3,418 | 5.0% | 02 Sep, 2026 |
| 6 | William K. Mcvicar | Director | 3,002 | 0 | 3,002 | 4.4% | 02 Sep, 2026 |
| 7 | Jonathan I Lieber | Director | 2,002 | 0 | 2,002 | 2.9% | 02 Sep, 2026 |
| 8 | Tess Burleson | Director | 2,002 | 0 | 2,002 | 2.9% | 02 Sep, 2026 |
| 9 | Paul Lammers | Director | 2,001 | 0 | 2,001 | 2.9% | 02 Sep, 2026 |
| 10 | Patricia G. Gauthier | Director | 2,000 | 0 | 2,000 | 2.9% | 02 Sep, 2026 |
| 11 | David J. Arthur | Chief Executive Officer | 10 | 0 | 10 | 0.0% | 15 Feb, 2023 |
| 12 | Bruce J Jr. Mccreedy | Director | 0 | 0 | 0 | 0.0% | 05 Jan, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 31 Aug, 2026 | Peter Klaus Marschel | Chief Business Officer | Acquired A | 3,900 | $0.00 | $0 | 3,900 | Direct |
| 31 Aug, 2026 | Arnold C Hanish | Director | Acquired A | 3,000 | $0.00 | $0 | 3,418 | Direct |
| 31 Aug, 2026 | William K. Mcvicar | Director | Acquired A | 3,000 | $0.00 | $0 | 3,002 | Direct |
| 31 Aug, 2026 | Jonathan I Lieber | Director | Acquired A | 2,000 | $0.00 | $0 | 2,002 | Direct |
| 31 Aug, 2026 | Tess Burleson | Director | Acquired A | 2,000 | $0.00 | $0 | 2,002 | Direct |
| 31 Aug, 2026 | Patricia G. Gauthier | Director | Acquired A | 2,000 | $0.00 | $0 | 2,000 | Direct |
| 31 Aug, 2026 | Mark J Rosenblum | Chief Financial Officer | Acquired A | 9,682 | $0.00 | $0 | 11,363 | Direct |
| 31 Aug, 2026 | Barbara Louise Hibner | Chief Scientific Officer | Acquired A | 4,216 | $0.00 | $0 | 4,216 | Direct |
| 31 Aug, 2026 | Paul Lammers | Director | Acquired A | 2,000 | $0.00 | $0 | 2,001 | Direct |
| 31 Aug, 2026 | Frederick Ii Pierce | Chief Executive Officer | Acquired A | 33,455 | $0.00 | $0 | 34,844 | Direct |
| 30 Dec, 2025 | Arnold C Hanish | Director | Disposed S | 15 | $575,701.21 | $8.64Mn | 0 | Indirect |
| 30 Dec, 2025 | Arnold C Hanish | Director | Disposed S | 12 | $575,701.21 | $6.91Mn | 0 | Direct |
| 20 Nov, 2025 | Arnold C Hanish | Director | Acquired P | 5,000 | $673,256.34 | $3.37Bn | 0 | Indirect |
| 20 Nov, 2025 | Mark J Rosenblum | Exec Vp Finance, Cfo | Acquired P | 20,000 | $719,964.00 | $14.40Bn | 0 | Direct |
| 11 Apr, 2024 | David J. Arthur | Chief Executive Officer | Acquired A | 20,500 | $0.00 | $0 | 4 | Direct |
| 20 Feb, 2024 | William K. Mcvicar | Director | Acquired A | 20,500 | $0.00 | $0 | 4 | Direct |
| 20 Feb, 2024 | Paul Lammers | Director | Acquired A | 20,500 | $0.00 | $0 | 4 | Direct |
| 20 Feb, 2024 | Jonathan I Lieber | Director | Acquired A | 20,500 | $0.00 | $0 | 4 | Direct |
| 20 Feb, 2024 | Mark J Rosenblum | Exec Vp Finance, Cfo | Acquired A | 22,500 | $0.00 | $0 | 5 | Direct |
| 20 Feb, 2024 | Arnold C Hanish | Director | Acquired A | 20,500 | $0.00 | $0 | 4 | Direct |